The impact of COVID-19 on the pharmaceutical industry has proven to be challenging, but also eye-opening.
Pharmaceutical companies have faced pressure to manage disturbances in supply coupled with unprecedented demand, which has led to uncertainty in the legal landscape. With this in mind, how can the industry best respond, and how will these changes impact the future of the pharmaceutical landscape?
Informa Connect reached out to some of this year's EU Pharmaceutical Law Forum speakers for advice on how best to mitigate the challenges facing the pharmaceutical industry.
Read on to discover what the legal experts had to say about the impact of COVID-19, and how the pharmaceutical industry can adapt in the current climate.
Jump to any article using the contents on the following page, or at any time using the Contents menu in the top left. There you can also download this eBook as a PDF.
Alexander Roussanov, Partner Arnold & Porter, Belgium
Annabelle Bryndonckx, Partner Vladimir Murovec, Supervising Associate Simmons & Simmons, Belgium
Ingrid Vandenborre, Partner Skadden, Arps, Slate, Meagher & Flom LLP , Belgium
Bart Van Vooren, Associate Peter Bogaert, Managing Partner Miranda Cole, Partner Covington and Burling LLP, Belgium
Sally Shorthose, Partner Bird & Bird, UK
William Long, Partner Sidley Austin LLP, UK
